SCHEMBL2393331

SCHEMBL2393331

COC(=O)c1ccn2c(CN)cnc2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 2/20 0.44
JMJD6 Q6NYC1 1/20 0.39
KDM4E B2RXH2 7/20 0.39
ALDH1A1 P00352 3/20 0.39
GLA P06280 2/20 0.39
GAA P10253 2/20 0.39
HPGD P15428 2/20 0.39
AKT1 P31749 1/20 0.39
AKT2 P31751 1/20 0.39
PLAU P00749 1/20 0.38
MAPK1 P28482 2/20 0.38
KDM4C Q9H3R0 2/20 0.38
KDM6B O15054 1/20 0.38
KDM5C P41229 1/20 0.38
KDM2A Q9Y2K7 1/20 0.38
KDM3A Q9Y4C1 1/20 0.38
FGFR3 P22607 1/20 0.37
KDR P35968 1/20 0.37
MAPT P10636 3/20 0.37
HSD17B10 Q99714 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2396747 0.88 JMJD6 (0.40) LOXL2JMJD6KDM4EALDH1A1GLA
SCHEMBL24492953 0.80 JMJD6 (0.43) JMJD6KDM4EALDH1A1GLAGAA
SCHEMBL557497 0.79 JMJD6 (0.42) JMJD6KDM4EALDH1A1GLAGAA
SCHEMBL2660202 0.79 JMJD6 (0.42) JMJD6KDM4EALDH1A1GLAGAA
SCHEMBL31379206 0.78 KDM5A (0.45) KDM4EALDH1A1PLAUFGFR3KDR
SCHEMBL24997460 0.77 ALDH1A1 (0.41) JMJD6KDM4EALDH1A1GLAGAA
SCHEMBL22588776 0.74 ADRA2B (0.57) FGFR3KDRADRA2B
SCHEMBL14255060 0.73 KDM4E (0.48) KDM4EALDH1A1GLAGAAHPGD
SCHEMBL24997458 0.73 KDM4E (0.39) JMJD6KDM4EALDH1A1GLAGAA
SCHEMBL2503035 0.73 JMJD6 (0.37) JMJD6KDM4EALDH1A1GLAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2079728-B1 N-ARYL PYRAZOLE COMPOUNDS FOR USE AGAINST DIABETES AMGEN INC (US) 2013-09-25 EP disclosed
US-8022061-B2 5-(Methoxymethyl)-1-(5-methyl-4-(thiophen-2-yl)pyrimidin-2-yl)-N-(pyridin-4-ylmethyl)-1H-pyrazole-4-carboxamide; for the treatment or prevention of type 2 diabetes and type 2 diabetes-related conditions AMGEN INC. (US) 2011-09-20 US disclosed
EP-2079728-A1 N-ARYL PYRAZOLE COMPOUNDS FOR USE AGAINST DIABETES Amgen Inc. (US) 2009-07-22 EP disclosed
US-20080153778-A1 N-aryl pyrazole compounds, compositions, and methods for their use AMGEN INC. 2008-06-26 US disclosed
WO-2008045484-A1 N-ARYL PYRAZOLE COMPOUNDS FOR USE AGAINST DIABETES AMGEN INC. (US) 2008-04-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153778-A1 N-aryl pyrazole compounds, compositions, and methods for their use GLP1R, GPR119, NAT1 LOXL2 937/4885JMJD6 3888/4885KDM4E 4209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.